Earl Davie

Last updated
Earl W. Davie
Born(1927-10-25)October 25, 1927
Tacoma, Washington
DiedJune 6, 2020(2020-06-06) (aged 92)
Bellevue, Washington
Education University of Washington (B.S., Ph.D.)
Scientific career
Fields Biochemistry
Institutions University of Washington

Earl Warren Davie (October 25, 1927 - June 6, 2020) was an American biochemist. He was a professor emeritus of biochemistry at the University of Washington. Davie studied the blood proteins involved in coagulation and was among the first scientists to describe the steps of the clotting process. He was a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. [1]

Contents

Early life

Davie was born on October 25, 1927, in Tacoma, Washington, [2] to Charles and Teckla Davie. He grew up in La Grande, Washington and attended Eatonville High School. [3] He received an undergraduate degree in 1950 from the University of Washington, where he had worked in the laboratory of biochemistry professor Donald Hanahan. [4] He completed a Ph.D. at UW in 1954. [5] During his doctoral studies, Davie worked with Hans Neurath to learn about protein structure and function. [4]

Career

After a postdoctoral fellowship with Fritz Lipmann at Harvard Medical School, Davie worked at the Case Western Reserve University School of Medicine from 1957 to 1962, where he met hematologist Oscar Ratnoff, the discoverer of Hageman factor (later known as factor XII). He then returned to the University of Washington, later chairing the biochemistry department for several years. [6]

Davie has made significant research contributions to the understanding of coagulation. Davie and Ratnoff described the sequence of steps in the clotting cascade. Davie and Ratnoff published their clotting cascade model in 1964, around the same time that Robert Gwyn Macfarlane of the University of Oxford produced a similar model. [7] Davie cofounded a biotechnology company, ZymoGenetics, in 1981. The company was purchased by Novo Nordisk several years later; in 2000, ZymoGenetics was recreated as an independent company and it was acquired by Bristol-Myers Squibb in 2010. [8]

Honors and awards

In 1980, Davie was elected to the National Academy of Sciences. [9] He was named a fellow of the American Academy of Arts and Sciences in 1987. [10] In 1993, Davie awarded the Stratton Medal from the American Society of Hematology; he was named a Legend in Hematology by the society in 2008. [11] He received a Distinguished Achievement Award from the American Heart Association in 1995. [12] The Centre for Blood Research at the University of British Columbia established the Earl W. Davie Symposium in his honor. [13]

Related Research Articles

<span class="mw-page-title-main">Michael Smith (chemist)</span> British-born Canadian biochemist, businessman and Nobel Prize laureate (1932–2000)

Michael Smith was a British-born Canadian biochemist and businessman. He shared the 1993 Nobel Prize in Chemistry with Kary Mullis for his work in developing site-directed mutagenesis. Following a PhD in 1956 from the University of Manchester, he undertook postdoctoral research with Har Gobind Khorana at the British Columbia Research Council in Vancouver, British Columbia, Canada. Subsequently, Smith worked at the Fisheries Research Board of Canada Laboratory in Vancouver before being appointed a professor of biochemistry in the UBC Faculty of Medicine in 1966. Smith's career included roles as the founding director of the UBC Biotechnology Laboratory and the founding scientific leader of the Protein Engineering Network of Centres of Excellence (PENCE). In 1996 he was named Peter Wall Distinguished Professor of Biotechnology. Subsequently, he became the founding director of the Genome Sequencing Centre at the BC Cancer Research Centre.

<span class="mw-page-title-main">Coagulation</span> Process of formation of blood clots

Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. It potentially results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair. The mechanism of coagulation involves activation, adhesion and aggregation of platelets, as well as deposition and maturation of fibrin.

<span class="mw-page-title-main">Thrombin</span> Enzyme involved in blood coagulation in humans

Thrombin is a serine protease, an enzyme that, in humans, is encoded by the F2 gene. Prothrombin is proteolytically cleaved to form thrombin in the clotting process. Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, as well as catalyzing many other coagulation-related reactions.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

<span class="mw-page-title-main">Factor XII</span> Mammalian protein involved in blood clotting

Coagulation factor XII, also known as Hageman factor, is a plasma protein. It is the zymogen form of factor XIIa, an enzyme of the serine protease class. In humans, factor XII is encoded by the F12 gene.

<span class="mw-page-title-main">ZymoGenetics</span> Former biotechnology company

ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA, based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East. It was closed in 2019 after its acquisition by Bristol Myers Squibb.

<span class="mw-page-title-main">Factor IX</span> Protein involved in blood clotting in humans

Factor IX is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B. It was discovered in 1952 after a young boy named Stephen Christmas was found to be lacking this exact factor, leading to haemophilia.

<span class="mw-page-title-main">Factor X</span> Mammalian protein found in Homo sapiens

Factor X, also known by the eponym Stuart–Prower factor, is an enzyme of the coagulation cascade. It is a serine endopeptidase. Factor X is synthesized in the liver and requires vitamin K for its synthesis.

<span class="mw-page-title-main">Factor XI</span> Mammalian protein found in Homo sapiens

Factor XI or plasma thromboplastin antecedent is the zymogen form of factor XIa, one of the enzymes of the coagulation cascade. Like many other coagulation factors, it is a serine protease. In humans, Factor XI is encoded by the F11 gene.

<span class="mw-page-title-main">Leo Sachs</span> Israeli molecular biologist (1924–2013)

Leo Sachs was a German-born Israeli molecular biologist and cancer researcher. Born in Leipzig, he emigrated to the United Kingdom in 1933, and to Israel in 1952. There he joined the Weizmann Institute of Science.

Kenneth Kaushansky, M.D., Master of the American College of Physicians (MACP) is an American medical doctor, hematologist, former editor of the medical journal Blood, and served as the dean of the Stony Brook University School of Medicine from 2010 to 2021. Prior to moving to Stony Brook, he was the Helen M. Ranney Professor, and chair of the department of medicine at University of California, San Diego School of Medicine.

Bernard Moss is a virologist at the National Institute of Allergy and Infectious Diseases, part of the United States National Institutes of Health. He is the Chief of the NIAID Laboratory of Viral Diseases and of the NIAID Genetic Engineering Section. He is known for his work on poxviruses.

William Albert Catterall is an American pharmacologist and neurobiologist, who researches ion channels. He currently serves as a professor of pharmacology at the University of Washington School of Medicine in Seattle, Washington and is known for the discovery of the sodium and calcium voltage-gated ion channels. Catterall received his B.A. in chemistry from Brown University in 1968 and his Ph.D. in physiological chemistry from Johns Hopkins University School of Medicine in 1972. He did his postdoctoral training in neurobiology and molecular pharmacology as a Muscular Dystrophy Association Fellow with Marshall Nirenberg at the NIH from 1972 to 1974. After three years as a staff scientist at the NIH, Catterall joined the University of Washington in 1977 as an associate professor of pharmacology. He earned full professorship in 1981 and served as chair of the University of Washington's pharmacology department from 1984 to 2016.

<span class="mw-page-title-main">Oscar Ratnoff</span> American hematologist and physician (1916–2008)

Oscar Davis Ratnoff was an American physician who conducted research on the process of coagulation and blood-related disorders. Ratnoff discovered the substance later known as Factor XII and was one of the primary contributors to the delineation of the exact sequence that makes up the clotting cascade. He also made notable research contributions to the understanding of the complement system and to the detection and treatment of hemophilia.

Philip Warren Majerus was an American biochemist who confirmed the cardiovascular benefits of aspirin. After graduating from medical school and completing a residency at Massachusetts General Hospital, Majerus conducted research at the National Heart Institute before becoming a faculty member at the Washington University School of Medicine.

Factor XII deficiency is a deficiency in the production of factor XII (FXII), a plasma glycoprotein and clotting factor that participates in the coagulation cascade and activates factor XI. FXII appears to be not essential for blood clotting, as individuals with this condition are usually asymptomatic and form blood clots in vivo. FXII deficiency tends to be identified during presurgical laboratory screening for bleeding disorders.

Eric Manvers Shooter was an English scientist known for investigating the biochemistry of nerve growth factor (NGF). From 1961 onwards he was affiliated with Stanford University School of Medicine, where he was founding chairman of the Department of Neurobiology (1975-1987).

<span class="mw-page-title-main">Christine Seidman</span>

Christine Edry Seidman is the Thomas W. Smith Professor of Medicine at Harvard Medical School and director of the Cardiovascular Genetics Center at Brigham and Women's Hospital. She operates a joint lab with her husband, Jonathan Seidman, where they study genetic mechanisms of heart disease. In recognition of her scientific contributions, she was elected as a fellow of the National Academy of Sciences, American Academy of Arts and Sciences, and National Academy of Medicine.

Jonathan G. Seidman is the Henrietta B. and Frederick H. Bugher Foundation Professor of Genetics at Harvard Medical School. He operates a joint lab with his wife, Christine Seidman, where they study genetic mechanisms of heart disease.

<span class="mw-page-title-main">Musa Mirmammad oglu Abdullayev</span> Azerbaijani medical doctor (1927-1979)

Musa Mirmammad oglu Abdullayev was a prominent Azerbaijani hematologist, doctor of medicine, professor, and philologist-translator. He was one of the eight members of the anti-Soviet nationalist student-youth political organization "Lightning" (İldırım), formed for the independence of Azerbaijan within 1942-1944.

References

  1. ↑ "Earl Davie, co-founder of ZymoGenetics and pioneer in blood-clotting research, dies at 93". The Seattle Times. 19 June 2020. Retrieved 1 October 2020.
  2. ↑ "1962: Blood Coagulation". UW Office of Research. November 1996. Archived from the original on August 25, 2015. Retrieved November 12, 2015.
  3. ↑ "Flintoft's Funeral Home & Crematory | Issaquah, WA Funeral Home & Cremation".
  4. 1 2 Kresge, Nicole; Simoni, Robert; Hill, Robert (December 1, 2006). "The waterfall sequence for blood clotting: The work of Earl W. Davie". Journal of Biological Chemistry . 281 (48): e39. doi: 10.1016/S0021-9258(20)72075-2 . Retrieved November 12, 2015.
  5. ↑ "Earl Davie". University of Washington . Retrieved November 12, 2015.
  6. ↑ "Earl W Davie, MD, PhD". Vallee Foundation. Retrieved November 12, 2015.
  7. ↑ Caen, Jacques; Wu, Qingyu (August 2010). "Hageman factor, platelets and polyphosphates: Early history and recent connection". Journal of Thrombosis and Haemostasis . 8 (8): 1670–1674. doi:10.1111/j.1538-7836.2010.03893.x. PMC   2965785 . PMID   20456750.
  8. ↑ "ZymoGenetics, a Bristol-Myers Squibb Company". Bristol-Myers Squibb . Retrieved November 12, 2015.
  9. ↑ "Earl W. Davie". National Academy of Sciences . Retrieved November 12, 2015.
  10. ↑ "Dr. Earl W. Davie". American Academy of Arts and Sciences . Retrieved November 12, 2015.[ permanent dead link ]
  11. ↑ "Legends in Hematology". American Society of Hematology . Retrieved November 12, 2015.
  12. ↑ "Earl W Davie, MD, PhD | The Vallee Foundation". www.thevalleefoundation.org. Retrieved May 17, 2020.
  13. ↑ "Earl W. Davie Symposium". Centre for Blood Research . Retrieved November 12, 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.